5-氯-2-甲氧基-4-甲氨基苯甲酸 | 61694-98-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氯-2-甲氧基-4-甲氨基苯甲酸
• 中文别名: 5-氯-2-甲氧基-4-(甲氨基)苯甲酸
• 英文名称: 5-chloro-2-methoxy-4-(methylamino)benzoic acid
• 英文别名: 4-(N-methylamino)-5-chloro-2-methoxybenzoic acid
• CAS: 61694-98-2
• 化学式: C₉H₁₀ClNO₃
• 分子量: 215.636
• InChiKey: TXJMYISJXPBNCC-UHFFFAOYSA-N

物化性质

• 熔点：
  183-184°C
• 沸点：
  373.4±42.0 °C(Predicted)
• 密度：
  1.370±0.06 g/cm3(Predicted)
• 溶解度：
  溶于氯仿

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2922509090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  5-氯-2-甲氧基-4-甲氨基苯甲酸 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 生成 nemonapride
  参考文献：
  名称：

  Synthesis and neuroleptic activity of benzamides. cis-N-(1-Benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide and related compounds

  摘要：

  Three series of benzamides of N,N-disubstituted ethylenediamines (linear alkane-1,2-diamines), 1-substituted 2-(aminomethyl)pyrrolidines, and 1-substituted 3-aminopyrrolidines (cyclic alkane-1,2-diamines) were designed and synthesized as potential neuroleptics. All target compounds were evaluated for their inhibitory effects on apomorphine-induced stereotyped behavior in rats, and a good correlation between structure and activity was found throughout the series. In the linear series (analogues of metoclopramide), introduction of a benzyl group on the terminal nitrogen, rather than an ethyl group, and a methyl group on the p-amino group of metoclopramide both enhanced the activity. The resulting N-[2-(N-benzyl-N-methylamino)ethyl]-5-chloro-2-methoxy-4-(methylamino) benzamide(23) was about 15 times more active than metoclopramide. In the cyclic series, particularly among the benzamides of 1-benzyl-3-aminopyrrolidine, most of the compounds tested were more active than the corresponding linear benzamides. cis-N-(1-Benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino) benzamide (YM-09151-2, 55) was the most active among all of the compounds tested, being 13 and 408 times more potent than haloperidol and metoclopramide, respectively. Moreover, compound 55 exhibited a fairly high ratio of antistereotypic activity to cataleptogenicity compared with haloperidol and metoclopramide. It is expected that compound 55 may be used as a potent drug with few side effects in the treatment of psychosis.

  DOI：

  10.1021/jm00142a019
• 作为产物：
  描述：

  4-(对甲苯磺酰基)氨基水杨酸 在 氢氧化钾 、 N-氯代丁二酰亚胺 、 硫酸 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 3.5h， 生成 5-氯-2-甲氧基-4-甲氨基苯甲酸
  参考文献：
  名称：

  4-氨基-5-氯-N-（1,4-二烷基六氢-1,4-二氮杂-6-6基）-2-甲氧基苯甲酰胺衍生物，新型有效的5-羟色胺5-HT3和多巴胺D2的合成及构效关系受体双重拮抗剂。

  摘要：

  为了寻找作为潜在的广泛止吐药的多巴胺D2和5-羟色胺5-HT3受体双重拮抗剂，从4-氨基-5-氯-2-甲氧基苯甲酸衍生物和6-氨基-1,4-制备了许多苯甲酰胺。分别使用大鼠脑突触膜和大鼠皮质膜评估二烷基六氢-1,4-二氮杂卓对多巴胺D2和5-羟色胺5-HT3受体的结合亲和力。从多巴胺D2受体的体外受体结合和体内生物学分析结果中，选择1-乙基-4-甲基六氢-1,4-二氮杂环作为最佳胺部分。在氮原子上的4-氨基-5-氯-2-甲氧基苯甲酰基基团的4-位引入一个甲基和/或在5-位取代基的修饰引起多巴胺D2受体结合的显着增加亲和力以及有效的5-HT3受体结合亲和力。在这些化合物中，5-氯-N-（1-乙基-4-甲基六氢-1,4-二氮杂-6-基）-2-甲氧基-4-甲基氨基苯甲酰胺（82），5-溴（110）和5 -碘（112）类似物对多巴胺D2受体的亲和力比对甲氧氯普胺的亲和力要高得多（IC50 = 17

  DOI：

  10.1248/cpb.50.941

文献信息

• Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides
  作者：Shiro Kato、Toshiya Morie、Katsuhiko Hino、Tatsuya Kon、Shunsuke Naruto、Naoyuki Yoshida、Tadahiko Karasawa、Junichi Matsumoto

  DOI：10.1021/jm00167a020

  日期：1990.5

  With the purpose of obtaining more potent and selective gastric prokinetic than metoclopramide (1), a new series of N-[(2-morpholinyl)alkyl]benzamides (17-52) were synthesized and their gastric prokinetic activity was evaluated by determining effects on the gastric emptying of phenol red semisolid meal and of resin pellets solid meal in rats and mice. The morpholinyl moiety was newly designed after

  为了获得比甲氧氯普胺（1）更有效和选择性的胃动力，合成了一系列新的N-[（2-吗啉基）烷基]苯甲酰胺（17-52），并通过测定对胃泌素的作用来评估其胃动力。大鼠和小鼠胃中酚红半固体粉和树脂颗粒固体粉的胃排空。考虑到西沙必利（2）的侧链结构后，新设计了吗啉基部分，并与甲氧氯普胺和西沙必利的4-氨基-5-氯-2-甲氧基苯甲酰基偶联时产生了所需的活性。苯甲酰基的取代基的改性显着影响了活性。特别是，
• 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides
  申请人：A. H. Robins Company, Inc.

  公开号：US04717563A1

  公开（公告）日：1988-01-05

  A method of controlling emesis caused by non-platinum anti-cancer drugs with 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides having the formula ##STR1## wherein X is oxygen or sulfur; R.sub.1 is loweralkyl; and R.sub.2 is selected from the group consisting of hydrogen, halo, 4,5-benzo, methylsulfonyl, loweralkoxy or Am and n is 1 or 2, and the pharmaceutically acceptable acid addition salts thereof is disclosed.

  一种控制由非铂类抗癌药物引起的呕吐的方法，使用具有通式##STR1##的2-烷氧基-N-(1-氮杂双环[2.2.2]辛-3-基)苯甲酰胺和噻吩甲酰胺，其中X为氧或硫；R1为低级烷基；R2选自氢、卤素、4,5-苯并、甲磺酰基、低级烷氧基或Am，n为1或2，以及其药学上可接受的酸加成盐。
• Method of enhancing memory or correcting memory deficiency with
  申请人：A. H. Robins Company, Inc.

  公开号：US04605652A1

  公开（公告）日：1986-08-12

  A pharmaceutical method for improving memory or correcting memory deficiency is disclosed, utilizing compounds having the formula: ##STR1## wherein n.sup.1, n.sup.2, n.sup.3, and n.sup.4 =0 to 3; R.sup.1, R.sup.2, R.sup.3, and R.sup.4 =H, loweralkyl or phenyl; R.sup.5 =H or loweralkyl; X=O or S; Ar=phenyl, substituted phenyl, pyridinyl, furanyl, thienyl, methoxy-1H-benzotriazolyl, indolinyl, methoxyindolinyl, methoxypyrimidinyl, amino-methoxypyrimadinyl, 1,3-benzodioxolyl, or naphthalenyl, and the pharmaceutically acceptable acid addition salts, hydrates and alcoholates thereof.

  本发明公开了一种改善记忆或纠正记忆缺陷的药物方法，采用具有以下通式的化合物：##STR1##其中n1、n2、n3和n4=0至3；R1、R2、R3和R4=H、低级烷基或苯基；R5=H或低级烷基；X=O或S；Ar=苯基、取代苯基、吡啶基、呋喃基、噻吩基、甲氧基-1H-苯并三唑基、吲哚啉基、甲氧基吲哚啉基、甲氧基嘧啶基、氨基-甲氧基嘧啶基、1,3-苯并二氧杂环己二烯基或萘基，以及它们的药学上可接受的酸加成盐、水合物和醇盐。
• A novel series of N-(hexahydr-1,4-diazepin-6-yl) and N-(hexahydroazepin-3-yl)benzamides with high affinity for 5-HT3 and dopamine D2 receptors
  作者：Yoshimi Hirokawa、Toshiya Morie、Hiroshi Yamazaki、Naoyuki Yoshida、Shiro Kato

  DOI：10.1016/s0960-894x(98)00078-x

  日期：1998.3

  A novel series of benzamides with a hexahydro-1,4-diazepine or hexahydroazepine ring in the amine moiety were prepared, and their binding affinities for 5-HT3 and dopamine D2 receptors were evaluated. The R isomer of the 1-ethyl-4-methylhexahydro-1,4-diazepinylbenzamide (R)-22 had potent affinity for both receptors. The R-enantiomer of the corresponding 1-ethylhexahydroazepinylbenzamide 28 showed potent

  制备了在胺部分具有六氢-1,4-二氮杂或六氢氮杂pine环的一系列新型苯甲酰胺，并评估了它们对5-HT3和多巴胺D2受体的结合亲和力。1-乙基-4-甲基六氢-1,4-二氮杂吡啶基苯甲酰胺（R）-22的R异构体对两种受体均具有强大的亲和力。相应的1-乙基六氢氮杂吡啶基苯甲酰胺28的R-对映异构体显示出对多巴胺D2受体的有效亲和力，而对5-HT3受体的亲和力降低，而S异构体是有效且选择性的5-HT3受体拮抗剂。
• Heterobimetallic Transition Metal/Rare Earth Metal Bifunctional Catalysis: A Cu/Sm/Schiff Base Complex for <i>Syn</i>-Selective Catalytic Asymmetric Nitro-Mannich Reaction
  作者：Shinya Handa、Vijay Gnanadesikan、Shigeki Matsunaga、Masakatsu Shibasaki

  DOI：10.1021/ja100514y

  日期：2010.4.7

  The full details of a catalytic asymmetric syn-selective nitro-Mannich reaction promoted by heterobimetallic Cu/Sm/dinucleating Schiff base complexes are described, demonstrating the effectiveness of the heterobimetallic transition metal/rare earth metal bifunctional catalysis. The first-generation system prepared from Cu(OAc)(2)/Sm(O-iPr)(3)/Schiff base 1a = 1:1:1 with an achiral phenol additive was

  描述了由异双金属 Cu/Sm/双核希夫碱配合物促进的催化不对称顺式选择性硝基-曼尼希反应的全部细节，证明了异双金属过渡金属/稀土金属双功能催化的有效性。由 Cu(OAc)(2)/Sm(O-iPr)(3)/Schiff 碱 1a = 1:1:1 与非手性酚添加剂制备的第一代系统部分成功地实现了同选择性催化不对称硝基-曼尼希反应。第一代系统的基板范围和局限性仍然存在问题。在对 Sm(O-iPr)(3) 制备的催化剂进行机理研究后，我们重新优化了催化剂的制备方法，与 Sm(O-iPr)(3) 相比，衍生自 Sm(5)O(O-iPr)(13) 的催化剂显示出更广泛的底物通用性以及更高的反应性和立体选择性。Sm(5)O(O-iPr)(13) 的优化体系适用于各种芳香族、杂芳香族和可异构化脂肪族 N-Boc 亚胺，得到 66-99% ee 的产物，syn/anti = >20:1 -13:1。还使用衍生自